Stem definition | Drug id | CAS RN |
---|---|---|
4380 | 93413-62-8 |
Dose | Unit | Route |
---|---|---|
50 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 572 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 45 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 5.42 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 3.50 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 4.90 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.70 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 8.40 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 29, 2008 | FDA | WYETH PHARMS INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Product residue present | 726.26 | 16.05 | 195 | 20904 | 3687 | 46661276 |
Drug withdrawal syndrome | 585.58 | 16.05 | 273 | 20826 | 27111 | 46637852 |
Suicidal ideation | 327.08 | 16.05 | 241 | 20858 | 56141 | 46608822 |
Anxiety | 270.67 | 16.05 | 370 | 20729 | 181587 | 46483376 |
Feeling abnormal | 267.14 | 16.05 | 305 | 20794 | 124755 | 46540208 |
Crying | 264.82 | 16.05 | 147 | 20952 | 20994 | 46643969 |
Withdrawal syndrome | 254.62 | 16.05 | 136 | 20963 | 17998 | 46646965 |
Insomnia | 216.38 | 16.05 | 316 | 20783 | 164608 | 46500355 |
Depression | 206.08 | 16.05 | 314 | 20785 | 169790 | 46495173 |
Irritability | 168.26 | 16.05 | 124 | 20975 | 28822 | 46636141 |
Dizziness | 151.30 | 16.05 | 414 | 20685 | 340000 | 46324963 |
Anger | 141.79 | 16.05 | 80 | 21019 | 11772 | 46653191 |
Nausea | 113.72 | 16.05 | 609 | 20490 | 686845 | 45978118 |
Hyperhidrosis | 109.48 | 16.05 | 166 | 20933 | 89142 | 46575821 |
Condition aggravated | 106.57 | 16.05 | 296 | 20803 | 244756 | 46420207 |
Headache | 105.73 | 16.05 | 461 | 20638 | 477891 | 46187072 |
Panic attack | 89.95 | 16.05 | 74 | 21025 | 20168 | 46644795 |
Nervousness | 84.70 | 16.05 | 83 | 21016 | 28392 | 46636571 |
Emotional disorder | 83.54 | 16.05 | 58 | 21041 | 12266 | 46652697 |
Intentional product misuse | 80.79 | 16.05 | 103 | 20996 | 47025 | 46617938 |
Agitation | 79.49 | 16.05 | 111 | 20988 | 55304 | 46609659 |
Abnormal dreams | 78.30 | 16.05 | 52 | 21047 | 10227 | 46654736 |
Tremor | 77.26 | 16.05 | 165 | 20934 | 115474 | 46549489 |
Feeling jittery | 75.06 | 16.05 | 52 | 21047 | 10956 | 46654007 |
Drug ineffective | 61.52 | 16.05 | 518 | 20581 | 677320 | 45987643 |
Thinking abnormal | 59.15 | 16.05 | 43 | 21056 | 9771 | 46655192 |
Nightmare | 56.23 | 16.05 | 52 | 21047 | 16546 | 46648417 |
Death | 49.85 | 16.05 | 47 | 21052 | 335501 | 46329462 |
Suicide attempt | 49.43 | 16.05 | 89 | 21010 | 54947 | 46610016 |
Serotonin syndrome | 48.05 | 16.05 | 57 | 21042 | 24163 | 46640800 |
Completed suicide | 47.08 | 16.05 | 159 | 20940 | 145761 | 46519202 |
Acute kidney injury | 46.97 | 16.05 | 24 | 21075 | 235831 | 46429132 |
Middle insomnia | 46.96 | 16.05 | 37 | 21062 | 9478 | 46655485 |
Anaemia | 45.30 | 16.05 | 30 | 21069 | 255749 | 46409214 |
Depressed mood | 45.18 | 16.05 | 65 | 21034 | 33254 | 46631709 |
Neutropenia | 44.53 | 16.05 | 6 | 21093 | 143198 | 46521765 |
Disturbance in attention | 43.42 | 16.05 | 62 | 21037 | 31498 | 46633465 |
Overdose | 42.99 | 16.05 | 122 | 20977 | 101857 | 46563106 |
Rheumatoid arthritis | 42.77 | 16.05 | 28 | 21071 | 240187 | 46424776 |
Pyrexia | 41.88 | 16.05 | 58 | 21041 | 348744 | 46316219 |
Paraesthesia | 41.49 | 16.05 | 132 | 20967 | 117305 | 46547658 |
Weight increased | 41.10 | 16.05 | 165 | 20934 | 164308 | 46500655 |
Migraine | 40.07 | 16.05 | 94 | 21005 | 69932 | 46595031 |
Mydriasis | 39.55 | 16.05 | 35 | 21064 | 10518 | 46654445 |
Mania | 38.73 | 16.05 | 35 | 21064 | 10811 | 46654152 |
Vision blurred | 38.22 | 16.05 | 100 | 20999 | 79608 | 46585355 |
Energy increased | 38.11 | 16.05 | 19 | 21080 | 2175 | 46662788 |
Anorgasmia | 37.63 | 16.05 | 13 | 21086 | 585 | 46664378 |
Tinnitus | 36.08 | 16.05 | 53 | 21046 | 27620 | 46637343 |
Drug screen positive | 35.35 | 16.05 | 22 | 21077 | 3869 | 46661094 |
Coma scale abnormal | 34.95 | 16.05 | 24 | 21075 | 4982 | 46659981 |
Impaired driving ability | 33.70 | 16.05 | 22 | 21077 | 4202 | 46660761 |
Thrombocytopenia | 33.53 | 16.05 | 8 | 21091 | 126573 | 46538390 |
Seizure | 32.78 | 16.05 | 126 | 20973 | 122928 | 46542035 |
Drug screen false positive | 32.78 | 16.05 | 13 | 21086 | 864 | 46664099 |
Product substitution issue | 32.53 | 16.05 | 37 | 21062 | 14994 | 46649969 |
Pneumonia | 32.26 | 16.05 | 77 | 21022 | 376243 | 46288720 |
Mood altered | 31.57 | 16.05 | 34 | 21065 | 12973 | 46651990 |
Blood pressure increased | 30.77 | 16.05 | 126 | 20973 | 126540 | 46538423 |
Aggression | 30.29 | 16.05 | 44 | 21055 | 22700 | 46642263 |
Prescribed overdose | 30.21 | 16.05 | 30 | 21069 | 10419 | 46654544 |
Sepsis | 29.92 | 16.05 | 12 | 21087 | 136002 | 46528961 |
Mood swings | 28.59 | 16.05 | 36 | 21063 | 16216 | 46648747 |
Drug hypersensitivity | 28.41 | 16.05 | 198 | 20901 | 243627 | 46421336 |
Hostility | 27.27 | 16.05 | 13 | 21086 | 1349 | 46663614 |
Bruxism | 27.26 | 16.05 | 17 | 21082 | 3000 | 46661963 |
Restlessness | 26.47 | 16.05 | 44 | 21055 | 25480 | 46639483 |
Somnolence | 26.43 | 16.05 | 140 | 20959 | 156381 | 46508582 |
Nonspecific reaction | 26.29 | 16.05 | 14 | 21085 | 1836 | 46663127 |
Amnesia | 25.03 | 16.05 | 57 | 21042 | 41574 | 46623389 |
Paranoia | 24.50 | 16.05 | 27 | 21072 | 10570 | 46654393 |
Libido decreased | 24.35 | 16.05 | 15 | 21084 | 2590 | 46662373 |
Maternal exposure during pregnancy | 24.33 | 16.05 | 8 | 21091 | 102541 | 46562422 |
Panic reaction | 24.15 | 16.05 | 17 | 21082 | 3672 | 46661291 |
Therapeutic response unexpected | 23.45 | 16.05 | 32 | 21067 | 15584 | 46649379 |
Palpitations | 23.31 | 16.05 | 95 | 21004 | 95164 | 46569799 |
Pre-existing condition improved | 22.94 | 16.05 | 21 | 21078 | 6591 | 46658372 |
Abnormal behaviour | 22.78 | 16.05 | 37 | 21062 | 21021 | 46643942 |
Dyspnoea | 22.41 | 16.05 | 139 | 20960 | 515409 | 46149554 |
Mental disorder | 22.38 | 16.05 | 38 | 21061 | 22387 | 46642576 |
Hypersensitivity vasculitis | 22.10 | 16.05 | 17 | 21082 | 4204 | 46660759 |
Euphoric mood | 21.92 | 16.05 | 17 | 21082 | 4255 | 46660708 |
Tachyphrenia | 21.87 | 16.05 | 11 | 21088 | 1283 | 46663680 |
Loss of libido | 21.43 | 16.05 | 11 | 21088 | 1338 | 46663625 |
Febrile neutropenia | 21.38 | 16.05 | 8 | 21091 | 94619 | 46570344 |
General physical health deterioration | 21.26 | 16.05 | 13 | 21086 | 115756 | 46549207 |
Apathy | 21.25 | 16.05 | 21 | 21078 | 7247 | 46657716 |
Post-traumatic stress disorder | 20.53 | 16.05 | 16 | 21083 | 4032 | 46660931 |
Muscle twitching | 20.43 | 16.05 | 29 | 21070 | 14643 | 46650320 |
Haemoglobin decreased | 20.37 | 16.05 | 17 | 21082 | 128932 | 46536031 |
Unevaluable event | 20.18 | 16.05 | 56 | 21043 | 46119 | 46618844 |
Bradycardia | 20.08 | 16.05 | 3 | 21096 | 66295 | 46598668 |
Drug effective for unapproved indication | 20.05 | 16.05 | 11 | 21088 | 1531 | 46663432 |
Negative thoughts | 20.03 | 16.05 | 9 | 21090 | 816 | 46664147 |
Urinary tract infection | 18.89 | 16.05 | 45 | 21054 | 220221 | 46444742 |
Stomatitis | 18.71 | 16.05 | 4 | 21095 | 68293 | 46596670 |
Intestinal pseudo-obstruction | 18.53 | 16.05 | 8 | 21091 | 659 | 46664304 |
Peripheral swelling | 18.21 | 16.05 | 27 | 21072 | 158044 | 46506919 |
Dissociation | 18.04 | 16.05 | 11 | 21088 | 1866 | 46663097 |
Blood cholesterol increased | 17.95 | 16.05 | 49 | 21050 | 39964 | 46624999 |
Treatment failure | 17.73 | 16.05 | 10 | 21089 | 93077 | 46571886 |
Suicidal behaviour | 17.72 | 16.05 | 12 | 21087 | 2436 | 46662527 |
Change in seizure presentation | 17.45 | 16.05 | 6 | 21093 | 266 | 46664697 |
Renal impairment | 17.29 | 16.05 | 6 | 21093 | 74366 | 46590597 |
Food craving | 16.92 | 16.05 | 9 | 21090 | 1178 | 46663785 |
Respiratory failure | 16.92 | 16.05 | 11 | 21088 | 94805 | 46570158 |
Coma | 16.86 | 16.05 | 3 | 21096 | 58346 | 46606617 |
Joint swelling | 16.69 | 16.05 | 31 | 21068 | 166042 | 46498921 |
Septic shock | 16.68 | 16.05 | 3 | 21096 | 57890 | 46607073 |
Hallucination | 16.58 | 16.05 | 55 | 21044 | 49896 | 46615067 |
Brain injury | 16.57 | 16.05 | 17 | 21082 | 6133 | 46658830 |
Stress | 16.44 | 16.05 | 56 | 21043 | 51495 | 46613468 |
Wrong technique in product usage process | 16.38 | 16.05 | 58 | 21041 | 54364 | 46610599 |
Impaired work ability | 16.18 | 16.05 | 24 | 21075 | 12612 | 46652351 |
Impatience | 16.13 | 16.05 | 6 | 21093 | 335 | 46664628 |
Affect lability | 16.11 | 16.05 | 19 | 21080 | 8001 | 46656962 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Product residue present | 227.03 | 23.59 | 60 | 5630 | 2618 | 29944170 |
Drug withdrawal syndrome | 162.71 | 23.59 | 78 | 5612 | 19731 | 29927057 |
Serotonin syndrome | 136.50 | 23.59 | 67 | 5623 | 17824 | 29928964 |
Suicidal ideation | 111.65 | 23.59 | 75 | 5615 | 36039 | 29910749 |
Anxiety | 96.24 | 23.59 | 101 | 5589 | 89770 | 29857018 |
Depression | 76.70 | 23.59 | 90 | 5600 | 90347 | 29856441 |
Overdose | 63.42 | 23.59 | 79 | 5611 | 84258 | 29862530 |
Suicide attempt | 61.67 | 23.59 | 53 | 5637 | 36644 | 29910144 |
Sexual dysfunction | 56.50 | 23.59 | 26 | 5664 | 5975 | 29940813 |
Hyperhidrosis | 52.26 | 23.59 | 64 | 5626 | 67026 | 29879762 |
Insomnia | 51.19 | 23.59 | 75 | 5615 | 93261 | 29853527 |
Drug ineffective | 50.43 | 23.59 | 160 | 5530 | 340227 | 29606561 |
Anger | 49.14 | 23.59 | 29 | 5661 | 11091 | 29935697 |
Withdrawal syndrome | 48.83 | 23.59 | 29 | 5661 | 11221 | 29935567 |
Feeling abnormal | 42.34 | 23.59 | 53 | 5637 | 56703 | 29890085 |
Thinking abnormal | 40.78 | 23.59 | 20 | 5670 | 5291 | 29941497 |
Completed suicide | 38.18 | 23.59 | 68 | 5622 | 99424 | 29847364 |
Mania | 33.09 | 23.59 | 21 | 5669 | 9133 | 29937655 |
Coma scale abnormal | 32.94 | 23.59 | 15 | 5675 | 3361 | 29943427 |
Dry mouth | 32.39 | 23.59 | 30 | 5660 | 22820 | 29923968 |
Nervousness | 30.54 | 23.59 | 22 | 5668 | 11766 | 29935022 |
Libido decreased | 28.64 | 23.59 | 15 | 5675 | 4551 | 29942237 |
Drug screen positive | 26.29 | 23.59 | 14 | 5676 | 4393 | 29942395 |
Headache | 26.18 | 23.59 | 85 | 5605 | 182221 | 29764567 |
Erectile dysfunction | 26.11 | 23.59 | 24 | 5666 | 18078 | 29928710 |
Abnormal behaviour | 25.90 | 23.59 | 28 | 5662 | 25595 | 29921193 |
Bipolar disorder | 25.39 | 23.59 | 13 | 5677 | 3763 | 29943025 |
Paralysis | 25.05 | 23.59 | 15 | 5675 | 5886 | 29940902 |
Irritability | 24.74 | 23.59 | 26 | 5664 | 23024 | 29923764 |
Paraesthesia | 24.59 | 23.59 | 40 | 5650 | 54287 | 29892501 |
Drug screen false positive | 24.49 | 23.59 | 8 | 5682 | 731 | 29946057 |
Tremor | 24.49 | 23.59 | 48 | 5642 | 75315 | 29871473 |
Emotional disorder | 24.39 | 23.59 | 14 | 5676 | 5080 | 29941708 |
Condition aggravated | 24.19 | 23.59 | 69 | 5621 | 137797 | 29808991 |
Acute kidney injury | 24.08 | 23.59 | 11 | 5679 | 273831 | 29672957 |
Vasoplegia syndrome | 23.81 | 23.59 | 9 | 5681 | 1262 | 29945526 |
Intentional product misuse | 23.66 | 23.59 | 31 | 5659 | 34636 | 29912152 |
Source | Code | Description |
---|---|---|
ATC | N06AX23 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Other antidepressants |
FDA MoA | N0000000102 | Norepinephrine Uptake Inhibitors |
FDA MoA | N0000000109 | Serotonin Uptake Inhibitors |
FDA EPC | N0000175749 | Serotonin and Norepinephrine Reuptake Inhibitor |
MeSH PA | D000928 | Antidepressive Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D014179 | Neurotransmitter Uptake Inhibitors |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D000068760 | Serotonin and Noradrenaline Reuptake Inhibitors |
FDA MoA | N0000182137 | Cytochrome P450 2D6 Inhibitors |
CHEBI has role | CHEBI:35469 | thymoanaleptics |
CHEBI has role | CHEBI:49103 | drug metabolites |
CHEBI has role | CHEBI:83399 | marine xenobiotic metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Major depressive disorder | indication | 370143000 | |
Generalized anxiety disorder | off-label use | 21897009 | DOID:14320 |
Social phobia | off-label use | 25501002 | DOID:11257 |
Menopausal flushing | off-label use | 198436008 | |
Neuropathic pain | off-label use | 247398009 | |
Panic disorder | off-label use | 371631005 | DOID:594 |
Ocular hypertension | contraindication | 4210003 | DOID:9282 |
Suicidal thoughts | contraindication | 6471006 | |
Hypercholesterolemia | contraindication | 13644009 | |
Bipolar disorder | contraindication | 13746004 | DOID:3312 |
Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Syndrome of inappropriate vasopressin secretion | contraindication | 55004003 | DOID:3401 |
Cerebrovascular disease | contraindication | 62914000 | DOID:6713 |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Hyponatremia | contraindication | 89627008 | |
Seizure disorder | contraindication | 128613002 | |
Bleeding | contraindication | 131148009 | |
Impaired renal function disorder | contraindication | 197663003 | |
Mania | contraindication | 231494001 | |
Hypomania | contraindication | 231496004 | |
Interstitial lung disease | contraindication | 233703007 | DOID:3082 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Hypertriglyceridemia | contraindication | 302870006 | |
Serotonin syndrome | contraindication | 371089000 | |
Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Myocardial infarction in recovery phase | contraindication | 418044006 | |
Hypertensive urgency | contraindication | 443482000 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.79 | acidic |
pKa2 | 9.33 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 100MG BASE | PRISTIQ | PF PRISM CV | N021992 | Feb. 29, 2008 | RX | TABLET, EXTENDED RELEASE | ORAL | Feb. 6, 2021 | ADDITION OF DATA BASED ON THE ASSESSMENT OF SAFETY AND EFFICACY IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER TO FULFILL POSTMARKETING STUDY REQUIREMENT 1229-1 |
EQ 25MG BASE | PRISTIQ | PF PRISM CV | N021992 | Aug. 20, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | Feb. 6, 2021 | ADDITION OF DATA BASED ON THE ASSESSMENT OF SAFETY AND EFFICACY IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER TO FULFILL POSTMARKETING STUDY REQUIREMENT 1229-1 |
EQ 50MG BASE | PRISTIQ | PF PRISM CV | N021992 | Feb. 29, 2008 | RX | TABLET, EXTENDED RELEASE | ORAL | Feb. 6, 2021 | ADDITION OF DATA BASED ON THE ASSESSMENT OF SAFETY AND EFFICACY IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER TO FULFILL POSTMARKETING STUDY REQUIREMENT 1229-1 |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Sodium-dependent noradrenaline transporter | Transporter | INHIBITOR | Ki | 6.27 | WOMBAT-PK | CHEMBL | |||
Sodium-dependent serotonin transporter | Transporter | INHIBITOR | Ki | 7.33 | WOMBAT-PK | CHEMBL | |||
Alpha-1A adrenergic receptor | GPCR | IC50 | 7.22 | CHEMBL |
ID | Source |
---|---|
D07793 | KEGG_DRUG |
4027338 | VUID |
N0000176142 | NUI |
93414-04-1 | SECONDARY_CAS_RN |
4027338 | VANDF |
C1880288 | UMLSCUI |
CHEBI:83527 | CHEBI |
CHEMBL1118 | ChEMBL_ID |
CHEMBL3989861 | ChEMBL_ID |
CHEMBL1201728 | ChEMBL_ID |
DB06700 | DRUGBANK_ID |
D000069468 | MESH_DESCRIPTOR_UI |
125017 | PUBCHEM_CID |
7158 | IUPHAR_LIGAND_ID |
8361 | INN_ID |
NG99554ANW | UNII |
683693 | RXNORM |
132507 | MMSL |
200628 | MMSL |
25184 | MMSL |
339716 | MMSL |
38906 | MMSL |
d07113 | MMSL |
012574 | NDDF |
012575 | NDDF |
015249 | NDDF |
430267008 | SNOMEDCT_US |
430271006 | SNOMEDCT_US |
433292007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Pristiq Extended-Release | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0008-1210 | TABLET, EXTENDED RELEASE | 25 mg | ORAL | NDA | 31 sections |
Pristiq Extended-Release | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0008-1211 | TABLET, EXTENDED RELEASE | 50 mg | ORAL | NDA | 31 sections |
Pristiq Extended-Release | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0008-1222 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | NDA | 31 sections |
Desvenlafaxine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0400 | TABLET, FILM COATED, EXTENDED RELEASE | 50 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0401 | TABLET, FILM COATED, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0603 | TABLET, FILM COATED, EXTENDED RELEASE | 25 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3659 | TABLET, EXTENDED RELEASE | 50 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3660 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-4060 | TABLET, EXTENDED RELEASE | 25 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | Human Prescription Drug Label | 1 | 35208-009 | TABLET, EXTENDED RELEASE | 50 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | Human Prescription Drug Label | 1 | 35208-010 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 30 sections |
PristiqExtended-Release | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-262 | TABLET, EXTENDED RELEASE | 50 mg | ORAL | NDA | 31 sections |
Desvenlafaxine | Human Prescription Drug Label | 1 | 46708-152 | TABLET, EXTENDED RELEASE | 50 mg | ORAL | NDA | 30 sections |
Desvenlafaxine | Human Prescription Drug Label | 1 | 46708-153 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | NDA | 30 sections |
Desvenlafaxine | Human Prescription Drug Label | 1 | 46708-540 | TABLET, EXTENDED RELEASE | 50 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | Human Prescription Drug Label | 1 | 46708-541 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | Human Prescription Drug Label | 1 | 46708-542 | TABLET, EXTENDED RELEASE | 25 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4069 | TABLET, EXTENDED RELEASE | 50 mg | ORAL | NDA AUTHORIZED GENERIC | 30 sections |
Desvenlafaxine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4388 | TABLET, EXTENDED RELEASE | 25 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4806 | TABLET, FILM COATED, EXTENDED RELEASE | 50 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | Human Prescription Drug Label | 1 | 50090-5274 | TABLET, EXTENDED RELEASE | 25 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | Human Prescription Drug Label | 1 | 50090-5293 | TABLET, EXTENDED RELEASE | 50 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-021 | TABLET, EXTENDED RELEASE | 25 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-022 | TABLET, EXTENDED RELEASE | 50 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-023 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | Human Prescription Drug Label | 1 | 51991-006 | TABLET, EXTENDED RELEASE | 25 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | Human Prescription Drug Label | 1 | 51991-311 | TABLET, EXTENDED RELEASE | 50 mg | ORAL | ANDA | 30 sections |
Desvenlafaxine | Human Prescription Drug Label | 1 | 51991-312 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 30 sections |
PristiqExtended-Release | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-2932 | TABLET, EXTENDED RELEASE | 50 mg | ORAL | NDA | 33 sections |
Desvenlafaxine Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59762-1210 | TABLET, EXTENDED RELEASE | 25 mg | ORAL | NDA AUTHORIZED GENERIC | 31 sections |